Top

Open Access 06-09-2024 | NSCLC | Original Article

Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival

Authors: Julia Ohlinger, Dirk Vordermark, Christian Ostheimer, Matthias Bache, Therese Tzschoppe, Kamil Demircan, Lutz Schomburg, PD Dr. med. Daniel Medenwald, Barbara Seliger

Published in: Strahlentherapie und Onkologie

Abstract

Background

Lung cancer remains a serious medical problem. The trace element selenium seems to be a promising prognostic marker or therapeutic option for cancer patients.

Methods

We enrolled 99 patients with histologically confirmed NSCLC undergoing radiotherapy. The serum selenium level of these patients was determined prior to irradiation (t0), after reaching 20 Gy (t1), and at the end of radiotherapy (t2). Selenium concentrations were measured with total-reflection X‑ray fluorescence (TXRF) spectroscopy. We formed three subgroups according to the change in serum selenium levels across timepoints, and Kaplan–Meier analysis was used to estimate overall survival (OS). Further subgroups were patients with/without metastatic disease. We used adjusted Cox regression models.

Results

The change in selenium concentration was especially significant between t0 and t1 for the whole study group (hazard ratio [HR] = 0.5, p = 0.03) as well as in patients with metastasized NSCLC (HR = 0.3, p = 0.04) after adjustment. The baseline selenium value in patients with non-metastasized NSCLC was associated with overall survival (HR = 0.3, p = 0.04). The change in selenium levels between t0 and t2 was significant in patients with metastatic lung cancer (HR = 0.1, p = 0.03). Patients with increased serum selenium levels during radiotherapy between the start of treatment (t0) and t1 had better OS (HR = 0.46, p = 0.05).

Conclusion

Especially patients with increasing selenium levels during radiotherapy showed an improved overall survival. Thus, serum selenium might be a predictive factor for OS in NSCLC patients. The value of supplementation of the trace element is subject to future research.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Delaney GP, Barton MB (2015) Evidence-based estimates of the demand for radiotherapy. Clin Oncol 27(2):70–76. https://doi.org/10.1016/j.clon.2014.10.005CrossRef

de Mello RA, Neves NM, Tadokoro H, Amaral GA, Castelo-Branco P, Zia VAA (2020) New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives. J Clin Med 9(11):3543. https://doi.org/10.3390/jcm9113543CrossRefPubMedPubMedCentral

Chen Y, Chen Z, Chen R, Fang C, Zhang C, Ji M, Yang X (2022) Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncol 18(14):1757–1775. https://doi.org/10.2217/fon-2021-0862CrossRefPubMed

Krug D, Dunst J (2023) Stereotaktische Radiotherapie plus Nivolumab bei NSCLC. Strahlenther Onkol 199(10):957–959. https://doi.org/10.1007/s00066-023-02143-0 (Stereotactic radiotherapy plus nivolumab in the treatment of non-small-cell lung cancer)CrossRefPubMedPubMedCentral

Hofstetter K, Taugner J, Käsmann L, Mansoorian S, Flörsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F (2023) First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis. Strahlenther Onkol. https://doi.org/10.1007/s00066-023-02175-6CrossRefPubMedPubMedCentral

Memmott RM, Wolfe AR, Carbone DP, Williams TM (2021) Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol 16(7):1086–1098. https://doi.org/10.1016/j.jtho.2021.03.017CrossRefPubMed

Puspitasari IM, Abdulah R, Yamazaki C et al (2014) Updates on clinical studies of selenium supplementation in radiotherapy. Radiat Oncol 9:125. https://doi.org/10.1186/1748-717X-9-125CrossRefPubMedPubMedCentral

Jaworska K, Gupta S, Durda K, Muszyńska M, Sukiennicki G, Jaworowska E, Grodzki T, Sulikowski M, Waloszczyk P, Wójcik J, Lubiński J, Cybulski C, Dębniak T, Lener M, Morawski AW, Krzystolik K, Narod SA, Sun P, Lubiński J, Jakubowska A (2013) A low selenium level is associated with lung and laryngeal cancers. PLoS ONE 8(3):e59051. https://doi.org/10.1371/journal.pone.0059051 (Erratum in: PLoS One. 2013;8(8). https://doi.org/10.1371/annotation/f777aaec-b6b8-4480-9cce-18e0f1b8e5d5)CrossRefPubMedPubMedCentral

10.

Kieliszek M, Bano I, Zare H (2022) A comprehensive review on selenium and its effects on human health and distribution in middle eastern countries. Biol Trace Elem Res 200(3):971–987. https://doi.org/10.1007/s12011-021-02716-zCrossRefPubMed

11.

Ibrahim SAZ, Kerkadi A, Agouni A (2019) Selenium and health: an update on the situation in the Middle East and North Africa. Nutrients 11(7):1457. https://doi.org/10.3390/nu11071457CrossRefPubMedPubMedCentral

12.

Schilling D, Herold B, Combs SE, Schmid TE (2019) Selenium does not affect radiosensitivity of breast cancer cell lines. Radiat Environ Biophys 58(3):433–438. https://doi.org/10.1007/s00411-019-00801-5CrossRefPubMed

13.

Lobb RJ, Jacobson GM, Cursons RT, Jameson MB (2018) The interaction of selenium with chemotherapy and radiation on normal and malignant human mononuclear blood cells. Int J Mol Sci 19(10):3167. https://doi.org/10.3390/ijms19103167CrossRefPubMedPubMedCentral

14.

Tian J, Wei X, Zhang W, Xu A (2020) Effects of selenium nanoparticles combined with radiotherapy on lung cancer cells. Front Bioeng Biotechnol 16(8):598997. https://doi.org/10.3389/fbioe.2020.598997CrossRef

15.

Handa E, Puspitasari IM, Abdulah R, Yamazaki C, Kameo S, Nakano T, Koyama H (2020) Recent advances in clinical studies of selenium supplementation in radiotherapy. J Trace Elem Med Biol 62:126653. https://doi.org/10.1016/j.jtemb.2020.126653CrossRefPubMed

16.

Hoeflich J, Hollenbach B, Behrends T, Hoeg A, Stosnach H, Schomburg L (2010) The choice of biomarkers determines the selenium status in young German vegans and vegetarians. Br J Nutr 104(11):1601–1604. https://doi.org/10.1017/S0007114510002618CrossRefPubMed

17.

Hughes DJ, Fedirko V, Jenab M, Schomburg L, Méplan C, Freisling H, Bueno-de-Mesquita HB, Hybsier S, Becker NP, Czuban M, Tjønneland A, Outzen M, Boutron-Ruault MC, Racine A, Bastide N, Kühn T, Kaaks R, Trichopoulos D, Trichopoulou A, Lagiou P, Panico S, Peeters PH, Weiderpass E, Skeie G, Dagrun E, Chirlaque MD, Sánchez MJ, Ardanaz E, Ljuslinder I, Wennberg M, Bradbury KE, Vineis P, Naccarati A, Palli D, Boeing H, Overvad K, Dorronsoro M, Jakszyn P, Cross AJ, Quirós JR, Stepien M, Kong SY, Duarte-Salles T, Riboli E, Hesketh JE (2015) Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int J Cancer 136(5):1149–1161. https://doi.org/10.1002/ijc.29071CrossRefPubMed

18.

Cabral M, Kuxhaus O, Eichelmann F, Kopp JF, Alker W, Hackler J, Kipp AP, Schwerdtle T, Haase H, Schomburg L, Schulze MB (2021) Trace element profile and incidence of type 2 diabetes, cardiovascular disease and colorectal cancer: results from the EPIC-Potsdam cohort study. Eur J Nutr 60(6):3267–3278. https://doi.org/10.1007/s00394-021-02494-3CrossRefPubMedPubMedCentral

19.

Baker JR, Umesh S, Jenab M, Schomburg L, Tjønneland A, Olsen A, Boutron-Ruault MC, Rothwell JA, Severi G, Katzke V, Johnson T, Schulze MB, Masala G, Agnoli C, Simeon V, Tumino R, Bueno-de-Mesquita HB, Gram IT, Skeie G, Bonet C, Rodriguez-Barranco M, Houerta JM, Gylling B, Van Guelpen B, Perez-Cornago A, Aglago E, Freisling H, Weiderpass E, Cross AJ, Heath AK, Hughes DJ, Fedirko V (2021) Prediagnostic blood selenium status and mortality among patients with colorectal cancer in Western European populations. Biomedicines 9(11):1521. https://doi.org/10.3390/biomedicines9111521CrossRefPubMedPubMedCentral

20.

Hughes DJ, Duarte-Salles T, Hybsier S, Trichopoulou A, Stepien M, Aleksandrova K, Overvad K, Tjønneland A, Olsen A, Affret A, Fagherazzi G, Boutron-Ruault MC, Katzke V, Kaaks R, Boeing H, Bamia C, Lagiou P, Peppa E, Palli D, Krogh V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Peeters PH, Engeset D, Weiderpass E, Lasheras C, Agudo A, Sánchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Hemmingsson O, Wareham NJ, Khaw KT, Bradbury KE, Cross AJ, Gunter M, Riboli E, Romieu I, Schomburg L, Jenab M (2016) Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr 104(2):406–414. https://doi.org/10.3945/ajcn.116.131672CrossRefPubMed

21.

Demircan K, Bengtsson Y, Sun Q, Brange A, Vallon-Christersson J, Rijntjes E, Malmberg M, Saal LH, Rydén L, Borg Å, Manjer J, Schomburg L (2021) Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: a multicentre cohort study. Redox Biol 47:102145. https://doi.org/10.1016/j.redox.2021.102145CrossRefPubMedPubMedCentral

22.

Pietrzak S, Wójcik J, Scott RJ, Kashyap A, Grodzki T, Baszuk P, Bielewicz M, Marciniak W, Wójcik N, Dębniak T, Masojć B, Pieróg J, Cybulski C, Gronwald J, Wojtyś M, Kubisa B, Sukiennicki G, Deptuła J, Waloszczyk P, Jakubowska A, Lubiński J, Lener MR (2019) Influence of the selenium level on overall survival in lung cancer. J Trace Elem Med Biol 56:46–51. https://doi.org/10.1016/j.jtemb.2019.07.010CrossRefPubMed

23.

Lubiński J, Marciniak W, Muszynska M, Jaworowska E, Sulikowski M, Jakubowska A, Kaczmarek K, Sukiennicki G, Falco M, Baszuk P, Mojsiewicz M, Kotsopoulos J, Sun P, Narod SA, Lubiński JA (2018) Serum selenium levels and the risk of progression of laryngeal cancer. PLoS ONE 13(1):e184873. https://doi.org/10.1371/journal.pone.0184873 (Erratum in: PLoS One. 2018 Mar 12;13(3):e0194469)CrossRefPubMedPubMedCentral

24.

Fraunholz I, Eberlein K, Schopohl B, Böttcher HD, Rödel C (2008) Selenium levels during the course of radiotherapy. No influence of irradiation on blood selenium concentration. Strahlenther Onkol 184(8):411–415. https://doi.org/10.1007/s00066-008-1867-6CrossRefPubMed

25.

Lopez-Saez JB, Senra-Varela A, Pousa-Estevez L (2003) Selenium in breast cancer. Oncology 64(3):227–231. https://doi.org/10.1159/000069312CrossRefPubMed

26.

Schomburg L (2022) Selenoprotein P—Selenium transport protein, enzyme and biomarker of selenium status. Free Radic Biol Med 191:150–163. https://doi.org/10.1016/j.freeradbiomed.2022.08.022CrossRefPubMed

27.

Franca CAS, Nogueira CR, Ramalho A, Carvalho ACP, Vieira SL, Penna ABRC (2011) Serum levels of selenium in patients with breast cancer before and after treatment of external beam radiotherapy. Ann Oncol 22(5):1109–1112. https://doi.org/10.1093/annonc/mdq547CrossRefPubMed

28.

Yadav SP, Gera A, Singh I, Chanda R (2002) Serum selenium levels in patients with head and neck cancer. J Otolaryngol 31(4):216–219. https://doi.org/10.2310/7070.2002.21096CrossRefPubMed

29.

Zeng YC, Xue M, Chi F, Xu ZG, Fan GL, Fan YC, Zheng MH, Zhong WZ, Wang SL, Zhang ZY, Chen XD, Wu LN, Jin XY, Chen W, Li Q, Zhang XY, Xiao YP, Wu R, Guo QY (2012) Serum levels of selenium in patients with brain metastases from non-small cell lung cancer before and after radiotherapy. Cancer Radiother 16(3):179–182. https://doi.org/10.1016/j.canrad.2011.11.003CrossRefPubMed

30.

Elango S, Samuel S, Khashim Z, Subbiah U (2018) Selenium influences trace elements homeostasis, cancer Biomarkers in squamous cell carcinoma patients administered with cancerocidal radiotherapy. Asian Pac J Cancer Prev 19(7):1785–1792. https://doi.org/10.22034/APJCP.2018.19.7.1785CrossRefPubMedPubMedCentral

31.

Muecke R, Schomburg L, Glatzel M, Berndt-Skorka R, Baaske D, Reichl B, Buentzel J, Kundt G, Prott FJ, Devries A, Stoll G, Kisters K, Bruns F, Schaefer U, Willich N, Micke O, German Working Group Trace Elements and Electrolytes in Oncology-AKTE. (2010) Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys 78(3):828–835. https://doi.org/10.1016/j.ijrobp.2009.08.013CrossRefPubMed

32.

Muecke R, Micke O, Schomburg L, Glatzel M, Reichl B, Kisters K, Schaefer U, Huebner J, Eich HT, Fakhrian K, Adamietz IA, Buentzel J, German Working Group Trace Elements and Electrolytes in Oncology-AKTE (2014) Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology: follow-up analysis of the survival data 6 years after cessation of randomization. Integr Cancer Ther 13(6):463–467. https://doi.org/10.1177/1534735414541963CrossRefPubMed

33.

Muecke R, Micke O, Schomburg L, Buentzel J, Kisters K, Adamietz IA (2018) Selenium in radiation oncology-15 years of experiences in Germany. Nutrients 10(4):483. https://doi.org/10.3390/nu10040483CrossRefPubMedPubMedCentral

34.

Chen YC, Prabhu KS, Mastro AM (2013) Is selenium a potential treatment for cancer metastasis? Nutrients 5(4):1149–1168. https://doi.org/10.3390/nu5041149CrossRefPubMedPubMedCentral

35.

Zachara BA, Marchaluk-Wiśniewska E, Maciag A, Pepliński J, Skokowski J, Lambrecht W (1997) Decreased selenium concentration and glutathione peroxidase activity in blood and increase of these parameters in malignant tissue of lung cancer patients. Lung 175(5):321–332. https://doi.org/10.1007/pl00007578CrossRefPubMed

36.

Chen QW, Zhu XY, Li YY, Meng ZQ. (2014) Epigenetic regulation and cancer (review). Oncol Rep 31(2):523–532. https://doi.org/10.3892/or.2013.2913CrossRefPubMed

Title: Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival
Authors: Julia Ohlinger
Dirk Vordermark
Christian Ostheimer
Matthias Bache
Therese Tzschoppe
Kamil Demircan
Lutz Schomburg
PD Dr. med. Daniel Medenwald
Barbara Seliger
Publication date: 06-09-2024
Publisher: Springer Berlin Heidelberg
Keywords: NSCLC
NSCLC
Radiotherapy
Lung Cancer
Lung Cancer
Lung Cancer
Cytostatic Therapy
Published in: Strahlentherapie und Onkologie
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-024-02276-w

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on modern management of frailty

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content